16.40

1.11% 0.18

Rallybio Corp (RLYB)

Overview News Price History Financials Discussions Forecast Stock Split

Rallybio Corp stock is traded at $16.40, with a volume of 5,517. It is up +1.11% in the last 24 hours and down -3.07% over the past month. Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Previous Close:

$16.22

Open:

$16.2

24h Volume:

5,517

Relative Volume:

0.29

Market Cap:

$87.13M

Revenue:

$858.00K

Net Income/Loss:

$-7.82M

P/E Ratio:

-11.31

EPS:

-1.4503

Net Cash Flow:

$-27.59M

1W Performance:

-2.24%

1M Performance:

-3.07%

6M Performance:

+91.81%

1Y Performance:

+265.48%

1-Day Range:

$16.20

$16.41

1-Week Range:

$16.16

$16.62

52-Week Range:

$3.6701

$17.57

Rallybio Corp Stock (RLYB) Company Profile

Name

Rallybio Corp

Sector

Healthcare (1051)

Industry

Biotechnology (594)

Phone

203- 859-3820

Address

234 CHURCH STREET, NEW HAVEN

Employee

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

RLYB's Discussions on Twitter

Compare RLYB vs VRTX, REGN, MRNA, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RLYB Rallybio Corp	16.40	87.13M	858.00K	-7.82M	-27.59M	-1.4503
VRTX Vertex Pharmaceuticals Inc	535.17	135.64B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	819.09	84.33B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	202.63	80.90B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	875.76	55.07B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	382.27	43.24B	5.76B	514.49M	1.10B	4.4813

Rallybio Corp Stock (RLYB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-09-25	Downgrade	H.C. Wainwright	Buy → Neutral
May-15-24	Downgrade	JP Morgan	Overweight → Neutral
Feb-07-24	Downgrade	Jefferies	Buy → Hold
Apr-17-23	Initiated	H.C. Wainwright	Buy
Apr-10-23	Initiated	Wedbush	Outperform
Dec-09-22	Initiated	JP Morgan	Overweight
Feb-22-22	Initiated	JMP Securities	Mkt Outperform
Aug-23-21	Initiated	Cowen	Outperform
Aug-23-21	Initiated	Evercore ISI	Outperform
Aug-23-21	Initiated	Jefferies	Buy

View All

Rallybio Corp Stock (RLYB) Latest News

Oct 20, 2026

Form 4 Rallybio Corp: Helen M. Boudreau (Director) For: 16 October - Investing.com Canada

Oct 20, 2026

Oct 16, 2026

Rallybio Corp SEC Filing (Oct 16, 2026) - Stock Titan

Oct 16, 2026

Oct 14, 2026

Form 4 Rallybio Corp: Robert Lorne Hopfner (Director) For: 12 October - Investing.com India

Oct 14, 2026

Form 4 Rallybio Corp: Robert Lorne Hopfner (Director) For: 12 October - Investing.com Nigeria

Oct 14, 2026

Form 4 Rallybio Corp: Robert Lorne Hopfner (Director) For: 12 October - Investing.com UK

Oct 14, 2026

A $215M financing would split ownership three ways in Rallybio (Nasdaq: RLYB)'s proposed Avenzo merger. - Stock Titan

Oct 14, 2026

Form 4 Rallybio Corp: Jonathan I. Lieber (CFO) For: 9 October - Investing.com Nigeria

Oct 14, 2026

Oct 09, 2026

Form 4 Rallybio Corp For: 9 October By Investing.com - Investing.com South Africa

Oct 09, 2026

Form 4 Rallybio Corp For: 2 October By Investing.com - Investing.com South Africa

Oct 02, 2026

The proposed Avenzo merger would pair $215M financing with an ownership split for Rallybio (RLYB) holders. - Stock Titan

Oct 02, 2026

Sep 29, 2026

Form 4 Rallybio Corp For: 28 September By Investing.com - Investing.com South Africa

Sep 29, 2026

Sep 28, 2026

Form 4 Rallybio Corp For: 28 September - Investing.com India

Sep 28, 2026

Form 4 Rallybio Corp For: 28 September By Investing.com - Investing.com Australia

Sep 28, 2026

Form 4 Rallybio Corp For: 28 September By Investing.com - Investing.com Nigeria

Sep 28, 2026

Form 4 Rallybio Corp For: 28 September By Investing.com - Investing.com UK

Sep 28, 2026

Sep 16, 2026

Rallybio (NASDAQ: RLYB) holders expected to own 2.8% of new Avenzo - Stock Titan

Sep 16, 2026

Sep 10, 2026

Rallybio (NASDAQ: RLYB) Announces CFO Jonathan Lieber's Shift to Part-Time Role Starting September 15, 2026 - Kalkine Media

Sep 10, 2026

Sep 09, 2026

Rallybio's Jonathan Lieber to Shift to Part-Time CFO Role - TradingView

Sep 09, 2026

Aug 26, 2026